Larvol Delta - AltruBio-Presents-New-Positive-Data-from-its-Completed-Phase-1b-Study-Evaluating-ALTB168-in-Patients-with-SteroidRefractory-or-TreatmentRefractory-Acute-GraftVersusHostDisease-at-the-64th-ASH-Annual-Meeting-2022

neihulizumab (ALTB-168) - AltruBio

https://www.globenewswire.com/news-release/2022/12/10/2571387/0/en/AltruBio-Presents-New-Positive-Data-from-its-Completed-Phase-1b-Study-Evaluating-ALTB-168-in-Patients-with-Steroid-Refractory-or-Treatment-Refractory-Acute-Graft-Versus-Host-Diseas.html

Dec 10, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next